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Abstract 
Diagnostic tools for the detection of early-stage oesophageal adenocarcinoma (OAC) 
are urgently needed. Our aim was to develop an accurate and inexpensive method using 
biofluids (plasma, serum, saliva or urine) for detecting oesophageal stages through to 
OAC (squamous; inflammatory; Barrett’s; low-grade dysplasia; high-grade dysplasia; 
OAC) using attenuated total reflection Fourier-transform infrared (ATR-FTIR) 
spectroscopy. ATR-FTIR spectroscopy coupled with variable selection methods, with 
successive projections or genetic algorithms (GA) combined with quadratic 
discriminant analysis (QDA) were employed to identify spectral biomarkers in biofluids 
for accurate diagnosis in a hospital setting of different stages through to OAC. Quality 
metrics (Accuracy, Sensitivity, Specificity and F-score) and biomarkers of disease were 
computed for each model. For plasma, GA-QDA models using 15 wavenumbers 
achieved 100% classification for four classes. For saliva, PCA-QDA models achieved 
100% for the inflammatory stage and high-quality metrics for other classes. For serum, 
GA-QDA models achieved 100% performance for the OAC stage using 13 
wavenumbers. For urine, PCA-QDA models achieved 100% performance for all 
classes. Selected wavenumbers using a Student’s t-test (95% confidence interval) 
identified a differentiation of the stages on each biofluid: plasma (929 cm-1 to 1,431 cm-
1, associated with DNA/RNA and proteins); saliva (1,000 cm-1 to 1,150 cm-1, associated 
with DNA/RNA region); serum (1,435 cm-1 to 1,573 cm-1, associated with methyl 
groups of proteins and Amide II absorption); and, urine (1,681 cm-1 to 1777 cm-1, 
associated with a high frequency vibration of an antiparallel β-sheet of Amide I and 
stretching vibration of lipids). Our methods have demonstrated excellent efficacy for a 
rapid, cost-effective method of diagnosis for specific stages to OAC. These findings 
suggest a potential diagnostic tool for oesophageal cancer and could be translated into 
clinical practice. 
 
Keywords: ATR-FTIR spectroscopy; Biofluids; Classification techniques; Diagnosis; 
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Introduction 
The rising incidence of oesophageal cancer over the past three decades coincides 
with a change in histologic type and primary tumour location.1 The incidence of 
oesophageal adenocarcinoma (OAC) in the Western world, which is a long-term 
complication of damage by gastro-oesophageal reflux, has been rising over recent 
decades.2 The mounting incidence of obesity, which encourages gastro-oesophageal 
reflux appears to be a key factor. The second factor is the reduced incidence of H. pylori 
infection and associated atrophic gastritis. In turn, these factors decrease the acidity and 
peptic activity of gastric juice, damaging oesophageal mucosa.2 
 There is a proven association between Barrett’s oesophagus (BO) and OAC as a 
result of chronic inflammation from gastro-oesophageal reflux disease (GORD).3 
Metaplastic cells in BO progress to OAC through intermediate histological stages of 
inflammation, low-grade dysplasia (LGD), high-grade dysplasia (HGD) and OAC. This 
transformation that takes several years.4 OAC is aggressive and usually presents late 
with a poor prognosis. 
BO is the only known precursor to OAC to date. GORD increases the risk of 
OAC by >40-fold compared with the general population.4 There remains a lack of 
insight into its natural history.5 Additionally, there are no reliable predictive biomarkers 
that might enable us to risk-stratify BO patients and identify those who would benefit 
most from endoscopic management.6 Finally, prospective studies have not established a 
clear survival benefit for screening and surveillance in BO.7 There are several 
guidelines regarding screening, surveillance and management of BO. All however fail 
to demonstrate clear evidence for an established benefit, cost-effectiveness and robust 
risk stratification for patients.8 
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A recent systematic review and meta-analysis conducted in 2017 confirmed that 
the risk of progression to HGD or OAC in BO patients is primarily determined by the 
presence or absence of LGD (OR 4.2 (2.1–8.5)).9 The progression of BO to HGD or 
adenocarcinoma is further significantly increased with increasing length of BO segment 
[OR 1.2 (1.1–1.3) per additional cm in length]. Furthermore, Krishnamoorthi et al.9 
confirmed that older age and being male are risk factors for disease progression to HGD 
and OAC. Finally, the meta-analysis suggests that use of a proton pump inhibitor (OR 
0.55 (95% CI 0.32; 0.96)) or statins (OR 0.48 (95% CI 0.31; 0.73)) significantly 
decreases the risk of progression to HGD or cancer.9 
Early detection and prevention are key strategies to manage OAC. Early 
detection of cancer or dysplasia in BO allows intervention at an early stage. The 
argument as to which BO patients are most likely to benefit from surveillance and 
management hinges on the high prevalence of BO and the low cancer incidence among 
unselected BO cases versus the burden of invasive treatment and the high morbidity and 
mortality of OAC.10 Methods investigated in the diagnosis of BO and establishment of 
LGD, HGD and OAC include high-resolution endoscopy,11 chromoendoscopy,12 
autofluorescence,13 narrow band imaging (NBI),14 and optical coherence tomography 
(OCT)15 amongst others.16-18 
Although these methods have been widely used in the diagnosis and differential 
diagnosis of oesophageal diseases, two main drawbacks are noted. Current diagnostic 
methods rely on the collection of biopsy samples at endoscopy, which is an invasive and 
poor sampling technique despite rigorous protocols. The second drawback involves 
significant inter- and intra-observer variability for the endoscopist and pathologist. The 
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need for simple, reproducible and real-time information on the disease state by non-
invasive methods has never been more relevant. 
Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy 
has been applied to detect various alterations in human tissues, cells or biofluids (urine, 
saliva, plasma, serum, cerebrospinal).19-21 The derived ATR-FTIR spectrum is a series 
of wavenumber absorbance intensities, which correspond to particular frequencies, 
including Amide I (1650 cm–1), Amide II (1550 cm–1), Amide III (1260 cm–1), 
carbohydrates (1155 cm–1), glycogen (1030 cm–1), lipids (1750 cm–1), asymmetric 
phosphate stretching vibrations (asPO2
–; 1225cm–1), symmetric phosphate stretching 
vibrations (sPO2
–; 1080 cm–1) and protein phosphorylation (970 cm–1). 
ATR-FTIR spectroscopy has been used to identify neoplasia in ovary,22 cervix,23 
breast,24 brain,25 prostate,26 lung,27 skin,28 thyroid,29 stomach,30 colon31 and pancreas.32 
Several groups have used IR spectroscopy for the detection of Barrett’s oesophagus and 
pre-cancerous changes in oesophageal tissues.33–36 To the best of our knowledge, ATR-
FTIR spectroscopy has never been applied to interrogate the oesophageal stages of 
transformation to OAC, employing the biofluids plasma, serum, saliva or urine. 
Herein we set out to develop an accurate, quick and inexpensive method using 
biofluids (plasma, saliva, serum or urine) towards detecting oesophageal stages through 
to OAC (normal; inflammatory; Barrett’s; low-grade dysplasia (LGD); high-grade 
dysplasia (HGD); and, OAC). This was using a derived FTIR spectral region, or 
combination of variables, that reflects a specific biochemical feature of disease in 
human bodily fluids. We employed successive projections algorithm (SPA) and genetic 
algorithm (GA) to select an appropriate subset of wavenumbers for quadratic 
discriminant analysis (QDA). This novel approach envisions translation of this approach 
to ready use by practicing physicians and surgeons. 
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Material and Methods 
Sample collection 
Patients were identified from Upper Gastro-intestinal Multi-Disciplinary Team 
meetings and local hospital Pathology databases. Potential participants were identified 
prospectively and consented for biofluids (blood for plasma or serum, urine or saliva) 
and tissue was taken between October 2017 and June 2019 in a clinic or endoscopy 
setting. A power test (t-test-based with a 95% confidence level) was performed to 
determine the minimum sample size at 80% power, where a total of 82 samples was 
suggested. We collected 120 (plasma), 127 (saliva), 124 (serum) and 126 (urine) 
samples, which surpass the power of 80%. Biofluid specimens were categorised as 
follows: i) plasma:  n=35 normal, n=18 inflammatory, n=27 Barrett’s, n=6 LGD, n=12 
HGD and n=22 OAC (set A); ii) saliva: n=38 normal, n=19 inflammatory, n=27 
Barrett’s, n=6 LGD, n=12 HGD and n=25 OAC (set B); iii) serum: n=36 normal, n=19 
inflammatory, n=28 Barrett’s, n=6 LGD, n=12 HGD and n=23 OAC (set C); iv) and, 
urine: n=38 normal, n=19 inflammatory, n=27 Barrett’s, n=6 LGD, n=11 HGD and 
n=25 OAC (set D).  
  Ethical approval was granted by the East of England - Cambridge Central 
Research Ethics Committee from 2015 (Archival gastro-intestinal tissue, blood, saliva 
and urine collection; REC reference: 18/EE/0069; IRAS project ID: 242639). Ethics 
was also granted from the parent University (STEMH 909 application). All biofluids 
were stored in appropriate containers initially in a fridge at 4°C for up to 2 h. Plasma or 
serum samples were generated according to local protocols. Urine samples were 
centrifuged at 2200 rpm. All biofluids were then stored at -80°C. 
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Prior to slide preparation, biofluids samples were left to thaw in the fridge at 
4°C.  Thirty μL of individual biofluids (plasma, serum, saliva or urine) were pipetted 
onto naked FisherBrand™ slides for ATR-FTIR spectral analysis.  Each slide was 
labelled with a specific GI (Gastrointestinal number) corresponding to its specific tissue 
pathological classification (i.e., squamous tissue to adenocarcinoma). All slides were 
left to dry prior to transportation in wooden slide boxes to the laboratory for spectral 
analysis. All of the samples were stored in a de-humidified glass container to prevent 
condensation and physical damage. 
ATR-FTIR spectroscopy 
Spectroscopic interrogation of biofluid samples was performed at the 
Biomedical Research Laboratory at the University of Central Lancashire (UK). 
Histological diagnoses were unknown to those who performed IR spectroscopy. IR 
spectra were obtained using a Bruker TENSOR 27 FTIR spectrometer with Helios ATR 
attachment containing a diamond crystal (Bruker Optics Ltd, Coventry, UK) and 
operated using OPUS 6.5 software. Spectra were acquired from 10 independent sample 
locations. Data acquisition parameters were: 8 cm−1 spectral resolution giving 4 cm−1 
data spacing, 32 scans, 6 mm aperture setting and 2× zero-filling factors. The ATR 
diamond crystal was washed with distilled water and dried with tissue paper between 
each sample and before each new slide. A background absorption spectrum (for 
atmospheric correction) was taken prior to each new sample. 
Data analysis and chemometric methods 
 The data import, pre-treatment and construction of chemometric classification 
models were implemented in MATLAB R2014a software (MathWorks, USA) by using 
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PLS Toolbox version 7.9.3 (Eigenvector Research, Inc., USA) and custom-made 
routines. Raw spectra were pre-processed by cutting between 1800 and 900 cm-1 (235 
wavenumbers at 4 cm-1 spectral resolution), followed by rubberband baseline-correction 
and normalisation to the Amide I peak (i.e., 1650 cm-1). Before constructing the 
multivariate classification models (principal component analysis quadratic discriminant 
analysis, PCA-QDA; successive projections algorithm quadratic discriminant analysis, 
SPA-QDA; genetic algorithm quadratic discriminant analysis, GA-QDA) the samples 
were divided into training (60%), validation (20%) and prediction (20%) sets by the 
classic Kennard–Stone (KS)37 uniform sampling algorithm applied to the IR spectra as 
shown in Table 1. The training samples were used in the modelling procedure, whereas 
the prediction set was only used in the final classification evaluation. The optimum 
number of variables for SPA-QDA and GA-QDA was determined according to an 
average risk G of misclassification. Such a cost function is calculated in the validation 
set as: 
G =
1
NV
∑ gn
NV
n=1          (1) 
where gn is defined as: 
𝑔𝑛 =
𝑟2(𝑥𝑛,𝑚𝐼(𝑛))
min𝐼(𝑚)≠𝐼(𝑛) 𝑟
2(𝑥𝑛,𝑚𝐼(𝑚))
                                                                                       (2) 
and 𝐼(𝑛) is the index of the true class for the nth validation object 𝑥𝑛. 
In this definition, the numerator is the squared Mahalanobis distance between 
object 𝑥𝑛 (of class index  𝐼(𝑛)) and the sample mean 𝑚𝐼(𝑛) of its true class. The 
denominator in Eq. (2) corresponds to the squared Mahalanobis distance between object 
𝑥𝑛 and the centre of the closest incorrect class. The minimum value of the cost function 
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(maximum fitness) is achieved when the selected variables from the original data are as 
close as possible to its true class and as distant as possible from its incorrect class in the 
validation set. The GA routine was carried out using 100 generations with 200 
chromosomes each. Crossover and mutation probabilities were set to 60% and 1%, 
respectively. Moreover, the algorithm was repeated three times, starting from different 
random initial populations. The best solution (in terms of fitness value) resulting from 
three realizations of the GA was employed. 
QDA classification score (𝑄𝑖𝑘) is estimated using the variance-covariance matrix 
for each class k and an additional natural logarithm term, as follows: 
𝑄𝑖𝑘 = (𝐱𝑖 − ?̅?𝑘)
T𝚺𝑘
−1(𝐱𝑖 − ?̅?𝑘) + log𝑒|𝚺𝑘| − 2 log𝑒 𝜋𝑘           (3) 
where 𝚺𝑘 is the variance-covariance matrix of class k; and, log𝑒|𝚺𝑘| is the natural 
logarithm of the determinant of the variance-covariance matrix of class k. QDA forms a 
separated variance model for each class and does not assume that different classes have 
similar variance-covariance matrices, different to what is assumed by linear 
discriminant analysis (LDA).38 
 The calculation of figures of merit is a recommended standard practice to test 
model performance.39 Herein, measures of test accuracy including sensitivity (portion of 
positive samples correctly classified), specificity (portion of negative samples correctly 
classified), and F-score, which is a general measurement of the model accuracy. These 
quality metrics are calculated using the following equations: 
Sensitivity (%) =
𝐓𝐏
𝐓𝐏+𝐅𝐍
× 𝟏𝟎𝟎        (3) 
Specificity (%) =  
𝐓𝐍
𝐓𝐍+𝐅𝐏
× 𝟏𝟎𝟎        (4) 
F-score =
𝟐×𝐒𝐄𝐍𝐒×𝐒𝐏𝐄𝐂
𝐒𝐄𝐍𝐒+𝐒𝐏𝐄𝐂
         (5) 
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where TP stands for true positives, TN for true negatives, FP for false positives and FN 
for false negatives. SENS stands for sensitivity and SPEC for specificity. 
All selected wavenumbers derived from SPA-QDA and GA-QDA for 
oesophageal stages [i.e., normal vs. inflammatory vs. Barrett’s vs. low-grade dysplasia 
(LGD) vs. high-grade dysplasia (HGD) vs. oesophageal adenocarcinoma (OAC)] were 
confirmed by a two-tailed Student’s t-test (95% confidence interval). 
 
Results 
The number of training, validation and prediction specimens (or spectra) in each 
biofluid category is summarised in Table 1. 
Plasma dataset. Fig. 1A shows the average raw IR spectra derived from blood plasma 
for six oesophageal stages (Normal vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. 
OAC), respectively. Overall, the IR spectra for oesophageal stages appear to overlap in 
the biochemical-cell fingerprint region (1800 cm-1 to 900 cm-1), making it difficult to 
distinguish any subtle but significant differences. On closer analysis, notable 
distinguishing peaks that represent lipid functional groups could be observed around 
1650 cm-1 (Amide I) and 1550 cm-1 (Amide II). In addition, peaks were observed in the 
region of 1050–1000 cm-1 (carbohydrates and collagen) and 1300 cm-1 to 1150 cm-1 
(Amide III and asPO2
-). The methyl groups of lipids and proteins major peaks could be 
found around 1400 cm-1, 1260 cm-1 (Amide III), 1225 cm-1 (vasPO2
-) and 1080 cm-1 
(vsPO2
-). To discriminate the six oesophageal stages, the spectral dataset was pre-
processed using baseline correction and normalisation using the Amide I peak (Figure 
1B). Average IR pre-processed spectra appear to overlap in the biochemical fingerprint 
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region (1800 cm-1 to 900 cm-1) making spectral observation and the discovery of 
markers or signatures difficult. Therefore, chemometric techniques such as PCA-QDA, 
SPA-QDA and GA-QDA algorithms were adopted to classify Normal vs. Inflammatory 
vs. Barrett’s vs. LGD vs. HGD vs. OAC based on their IR spectra. 
 A classification of the six oesophageal stages was developed by discriminant 
analysis using the IR spectra between 900 and 1800 cm-1. Figure 1C shows the 
wavenumbers associated with class differences. The classification performance in the 
prediction set using GA-QDA was 100% accuracy, sensitivity, specificity and F-scores. 
Fig. 1D shows the predicted class achieved by the GA-QDA model for all classes based 
on 15 selected wavenumbers. An excellent classification of the samples was observed 
(only 3 errors in the training set and 1 error in the validation set). The PCA-QDA model 
using the scores on seven PCs (90% of the total data variance) achieved 100% for 
accuracy, sensitivity, specificity and F-scores for Normal, Inflammatory, Barrett’s and 
OAC classes [see Supplementary Information (SI) Table S1]. SPA-QDA also achieved 
a very high accuracy for classification of LGD (100%) using 7 variables (namely, 1392, 
1485, 1539, 1585, 1624, 1643, and 1681 cm-1), as shown in Table S1 (see SI). Table S2 
(see SI) lists the selected wavenumbers obtained by SPA-QDA and GA-QDA models 
for plasma samples with their tentative biomolecular assignments. 
Saliva dataset. Figure 2A and 2B show the raw average IR spectra and average pre-
processed (baseline correction and normalisation) in the biochemical-cell fingerprint 
region (1,800 cm-1 to 900 cm-1) derived from the saliva for six oesophageal stages. 
There are notable differences in the wavenumber regions 1,000 cm-1 to 1,150 cm-1 
(DNA/RNA region), 1,350 cm-1 to 1,500 cm-1 (Amide II protein region) and 1,530 cm-1 
to 1,600 cm-1 (Amide I protein region) for all classes investigated. Although there is 
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some overlap amongst the average pre-processed spectra, the application of 
chemometric techniques (PCA-QDA, SPA-QDA or GA-QDA) exhibits good 
categorisation for all the classes (Normal vs. Inflammatory vs. Barrett’s vs. LGD vs. 
HGD vs. OAC) (see SI Table S3). 
As shown in Table S3 (see SI), classification of the six stages using saliva and 
the FTIR spectra between 900 and 1800 cm-1 using all models (PCA-QDA, SPA-QDA 
and GA-QDA) gives excellent classification accuracy (88.8–100%), though poor 
specificity in the LGD class using PCA-QDA and GA-QDA. SPA-QDA is the best 
classification model for saliva, with F-Score values ranging from 76.9 to 100%. The 
correct classification using PCA-QDA achieved 100% for all figures of merits for the 
inflammatory category in the prediction set. The accuracy and sensitivity were found to 
be >88% for all the other classes, using the scores on seven PCs from PCA (Figure 2C). 
The number of PCs is selected in Figure 2C based on the minimum number of PCs that 
generates the lowest power (eigenvalue), before the power follows a constant trend. Fig. 
2D shows the predicted class achieved for PCA-QDA model for all classes. A good 
classification of the samples was observed (15 errors in the training set and 4 errors in 
the validation set). For SPA-QDA, 7 selected wavenumbers (902, 1014, 1099, 1589, 
1643, 1697, and 1743 cm-1) provided excellent classification, especially for the LGD 
class (100% predictive performance). The classification performance using GA-QDA 
was 100% for all figures of merit for the Barrett’s class based on 14 selected 
wavenumbers (991, 1003, 1068, 1107, 1431, 1558, 1585, 1604, 1624, 1689, 1701, 1716, 
1778 and 1786 cm-1). Table S4 (see SI) lists the selected wavenumbers obtained by 
SPA-QDA and GA-QDA models for saliva samples with their tentative biomolecular 
assignments. 
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Serum dataset. Figures 3A and 3B show the average raw and pre-processed spectra for 
serum samples obtained from the six oesophageal stages. Classification of Normal vs. 
Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC for serum was performed using 
discriminant analysis of the spectral bio-fingerprint region (1800-900 cm-1). GA-QDA, 
using only 13 selected wavenumbers (1000, 1315, 1319, 1330, 1338, 1435, 1442, 1446, 
1492, 1539, 1573, 1600 and 1654 cm-1; Fig. 3C) achieved 100% for all figures of merit 
for all the OAC stage, as shown in Table S5 (see SI). The GA-QDA model 
demonstrated an excellent classification with 4 errors in the training set and 2 errors in 
the validation set (Figure 3D). For Normal vs. Inflammatory vs. Barrett’s vs. OAC 
stages, the SPA-QDA model demonstrated sensitivities and specificities more than 71% 
(see SI Table S5) using only 7 variables (1041, 1477, 1539, 1593, 1631, 1662 and 1743 
cm-1). The PCA-QDA models for normal vs. Inflammatory vs. Barrett’s vs. OAC stages 
produced sensitivity and specificity greater than 71% using seven PCA scores, which 
accounted for more than 90% of original data variance. Some notable differences can be 
observed in the wavenumber regions between 1,000 cm-1 to 1,338 cm-1 (DNA/RNA 
region), 1,435 cm-1 to 1,573 cm-1 (methyl groups of proteins and protein amide II 
absorption) and 1,600 cm-1 to 1,654 cm-1 (Amide I protein region) for all of the classes 
investigated. Table S6 (see SI) lists the selected wavenumbers obtained by SPA-QDA 
and GA-QDA models for serum samples with their tentative biomolecular assignments. 
Urine dataset. Figure 4A and 4B show the raw and average pre-processed (baseline 
correction and normalization) spectral within the bio-fingerprint region (1,800 cm-1 to 
900 cm-1) derived from urine for all the six oesophageal stages. Although the 
discrimination for all classes on the basis of IR spectra is not straightforward due to the 
complexity of the spectra, good models using PCA-QDA, SPA-QDA and GA-QDA 
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were found for urine. The PCA-QDA model using urine spectra achieved 100% of 
classification for all figures of merit (accuracy, sensitivity, specificity and F-scores) for 
test samples using seven PCA scores as shown in Figure 4C. Fig. 4D demonstrated that 
the predicted classification performance achieved by the PCA-QDA model for all 
classes was 100%. As demonstrated in Table S7 (see SI), both SPA-QDA and GA-QDA 
models for urine samples achieved high sensitivity values for all classes (78.2–100%), 
but poor specificities particularly for Normal (SPA-QDA = 35.5%, GA-QDA = 62.5%), 
HGD (SPA-QDA = 33.3%) and OAC (SPA-QDA and GA-QDA = 20%). 
The SPA-QDA model using only 7 selected wavenumbers (9096, 1242, 1577, 
1600, 1651, 1681 and 1712 cm-1) achieved also good classification, especially for 
Inflammatory, Barrett’s and LGD classes. The predicted classification rate using GA-
QDA demonstrates good results for Barrett’s and HGD classes based on 19 selected 
wavenumbers (956, 995, 1018, 1030, 1095, 1118, 1141, 1253, 1334, 1381, 1431, 1446, 
1500, 1550, 1562, 1681, 1724, 1735 and 1777 cm-1). Spectral differences can be 
observed in the wavenumber regions between 956 cm-1 to 1,381 cm-1 (DNA/RNA 
region), 1,431 cm-1 to 1,562 cm-1 (Amide II region mainly stems from the C-N 
stretching and C-N-H bending vibrations) and 1,681 cm-1 to 1777 cm-1 (a high 
frequency vibration of an antiparallel β-sheet of Amide I and stretching vibration of 
lipids). Table S8 lists the selected wavenumbers obtained by SPA-QDA and GA-QDA 
models for urine samples with their tentative biomolecular assignments. 
Discussion 
There is no standard surveillance program for early detection of cancer in the 
oesophagus. The most reliable diagnostic measurement uses endoscopy with biopsy, 
which is advocated for screening oesophageal neoplasia especially in known high-risk 
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patients. Although endoscopy has been widely used in diagnosis and differential 
diagnosis of oesophageal diseases, approximately 20% of early oesophageal cancer 
lesions are barely visible to the naked eye. In order to have a robust surveillance 
program for early detection and improved cure rate for oesophageal adenocarcinoma, a 
skilled endoscopist and pathologist are necessary for proper mucosal sampling and 
histopathologic examination. However, the development of a quick, convenient, and 
inexpensive method for detecting early cancer or different stages such as Normal, 
Inflammatory, Barrett’s, LGD, HGD and OAC can be useful specially to guide tissue 
biopsy, thus increasing the yield of dysplasia detection. 
 An approach to oesophageal cancer screening in the general population based on 
biofluids (blood plasma, serum, saliva and urine) interrogated by ATR-FTIR 
spectroscopy linked with feature selection methods for classification could be the 
potential to segregate stages of oesophageal adenocarcinoma. The use of ATR-FTIR 
spectroscopy coupled multivariate classification techniques (PCA-QDA, SPA-QDA and 
GA-QDA) in identifying oesophageal stages of disease to adenocarcinoma has achieved 
excellent accuracy, sensitivity and specificity, encouraging investigation of screening 
for others cancers with known markers. 
ATR-FTIR spectroscopy was employed to predict six oesophageal stages in four 
different biofluids (plasma, saliva, serum and urine). PCA-QDA and GA-QDA models 
were found to give the best class differentiation compared to the SPA-QDA. GA-QDA 
successfully detected the biochemical alterations in the oesophageal stages based on 
plasma (100% accuracy, sensitivity, specificity and F-scores) using a few wavenumbers 
or biomarkers. For this model, several selected wavenumbers appear to be of particular 
interest, especially at 999 cm-1 and 1381 cm-1, representing the ring stretching vibrations 
mixed strongly with CH in-plane bending and C-O stretching, respectively. Others 
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selected wavenumbers found by GA-QDA using plasma can be found in Table S2. In 
general, the spectral alterations responsible for discrimination of oesophageal stages 
based on plasma blood were mainly associated with DNA/RNA and proteins at 
wavenumbers between 929 cm-1 and 1,431 cm-1. The major advantage for this model, 
using blood plasma, is the minimal sample preparation for FTIR analysis. 
Since a direct, easy-to-use, compact test device for oesophageal stages in human 
saliva is currently not available, we suggest ATR-FTIR spectroscopy combined with 
multivariate classification techniques for the development of a direct test that meets 
these challenges. Although saliva has a complex biology (components are produced 
mainly by acinar cells and are delivered to the oral cavity by a cell-lined duct system), 
we believe that saliva analysis based on ATR-FTIR is a powerful diagnostic tool in 
cancer. As demonstrated by the PCA-QDA model, the oesophageal stages diagnostic 
based on the saliva spectral data was found to have good accuracy, sensitivity, 
specificity and F-scores values for all classes, especially for the Inflammatory 
oesophageal stage. The selected wavenumbers found by SPA-QDA and GA-QDA 
models using saliva samples can be found in Table S2 (see SI). Several selected 
wavenumbers appear to be of particular interest, namely, the variables at 1604, 1624 
and 1643 cm-1, representing the adenine vibration in DNA, peak of nucleic acids due to 
the base carbonyl stretching, and ring breathing mode and amide I band (arises from 
C=O stretching vibrations), respectively. 
The classification rates for plasma samples were found to be better than those of 
saliva and serum for all classes. One explanation for such a difference is that plasma 
contains thousands of biomolecules at various concentrations while serum and saliva 
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may contain a more limited number of analytes resulting in fewer variations in peak 
intensities or shifts of the IR spectrum.  
Problems can arise with liquid samples, such as urine, because very low 
concentration components may not be detected. Low concentrations can be overcome 
by drying samples directly on to the crystal to increase their concentrations and, 
therefore, increase their signal intensities. We believe that clinically relevant levels 
could be detected in ATR-FTIR spectra of dried insoluble fractions of urine samples 
without any requirement for chemical manipulation. Urine can be collected non-
invasively and without the need for a trained professional to be present. It can also be 
collected frequently and stored for several days. It is therefore ideal as a diagnostic 
medium if it can provide clinically useful information. Urine samples for this present 
study demonstrated excellent discrimination for all stages using urine samples based on 
PCA-QDA models. SPA-QDA and GA-QDA presented relatively well segregation 
amongst all the classes using a few selected wavenumbers, as can seen in Table S8 (see 
SI). Despite relatively high values of accuracies and sensitivities, these two algorithms, 
in particular SPA-QDA, produced low specificity values (<50%) for classes Normal, 
HGD, and OAC (Table S7). The specificity is a measure of the classification fail 
towards one class. For example, a specificity of 100% in OAC means that no 
misclassification in the other 5 classes was assigned as OAC (there is no false positive 
for OAC); while a specificity of 20% in OAC means that most samples wrongly 
classified in this model were assigned as OAC. This affects the model classification 
performance, despite the satisfactory values of accuracy and sensitivity in general. Thus, 
for urine samples, PCA-QDA is the most reliable model.  
18 
 
The classification performance of the spectroscopy-based models to determine 
oesophageal stage are a result of a combination between the algorithm being used and 
the nature of the sample measured. Although the type of classifier employed in this 
study is the same for all algorithms (QDA), the feature extraction (PCA) and feature 
selection (SPA and GA) methods work in different manner, thus leading the models to 
different results. PCA reduces the spectral dataset to features representing the main 
sources of variance in the data, but not necessarily these sources of variation are 
correlated with differences between the samples; and, SPA and GA, which are iterative 
algorithms of variable selection, work by reducing data collinearity (SPA) and by 
mimicking the process of natural selection in a computation fashion (GA).40 Differently 
from PCA, both SPA and GA act on the original sample space, while PCA projects the 
sample on a orthogonal space; and SPA and GA are more complex algorithms, where 
more parameters need to be optimized and the computational-cost is higher. Therefore, 
choosing the right algorithm for data analysis is an empirical process. 
Spectroscopy of urine has been already used to diagnostic several cancers, such 
as endometrial and ovarian cancer, where different spectral markers were found to be 
associated with the pathologic stage.41 Molecular signatures of oesophageal cancer and 
Barrett’s oesophagus have been found in urine;42 and other biofluids, such as blood43 
and saliva,44 are known to contain key molecular signatures related to oesophageal 
cancer. For these reasons, and confirmed by the results reported herein, we believe that 
IR spectroscopy can be used to discriminate oesophageal transformation to 
adenocarcinoma based on these biofluids. 
 
Conclusion 
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The results of this study show that ATR-FTIR spectroscopy coupled with 
multivariate classification algorithms (PCA-QDA, SPA-QDA and GA-QDA), result in a 
powerful alternative approach for detection of oesophageal stages of disease to OAC. 
Herein, we present a new, rational and convenient approach to different biofluids 
(plasma, saliva, serum and urine) using ATR-FTIR spectroscopy, opening a new level 
of non-invasive diagnostic tool in this field. We also demonstrate a fast, clean, and non-
destructive methodology involving minimal sample preparation to categorise the 
samples. For urine samples, the resulting PCA-QDA model successfully detect 
biochemical alterations at the maximum classification rate (100%) for different figures 
of merit (accuracy, sensitivity, and F-scores). This method makes it possible to detect 
all the oesophageal stages to adenocarcinoma without special sample preparation and 
reagents, from a minimal sample volume and (almost) immediately after sample 
collection. In this pilot study, we have demonstrated for the first time that saliva- and 
urine-based ATR-FTIR spectroscopy coupled with a multivariate classification 
algorithm has the potential to discriminate oesophageal stages. Further work with 
biofluids and spectroscopic analysis should be performed in the future to validate these 
encouraging results. 
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Figures Captions 
Figure 1: Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using plasma samples. The panel shows: (A) Average raw in mid-IR region of 
1800 cm-1 to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages 
segregated into Normal (black colour) vs. Inflammatory (blue colour) vs. Barrett’s 
(green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour). (C) 15 selected wavenumbers by GA-QDA. (D) Predicted class vs. samples 
used for training and prediction sets (dashed box), where each circle marker represents 
one sample. 
Figure 2: Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using saliva samples. The panel shows: (A) Average raw in mid-IR region of 
1800 cm-1 to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages 
segregated into Normal (black colour) vs. Inflammatory (blue colour) vs. Barrett’s 
(green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour). (C) Singular value decomposition (SVD) vs. Number of principal component 
(PC) obtained by PCA-QDA, where Power represents the eigenvalue. (D) Predicted 
class vs. samples used for training and prediction sets (dashed box), where each circle 
marker represents one sample. 
Figure 3: Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using serum samples. The panel shows: (A) Average raw in mid-IR region of 
1800 cm-1 to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages 
segregated into Normal (black colour) vs. Inflammatory (blue colour) vs. Barrett’s 
(green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour). (C) 13 selected wavenumbers by GA-QDA. (D) Predicted class vs. samples 
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used for training and prediction sets (dashed box), where each circle marker represents 
one sample. 
Figure 4: Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using urine samples. The panel shows: (A) Average raw in mid-IR region of 
1800 cm-1 to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages 
segregated into Normal (black colour) vs. Inflammatory (blue colour) vs. Barrett’s 
(green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour). (C) Singular value decomposition (SVD) vs. Number of principal component 
(PC) obtained by PCA-QDA, where Power represents the eigenvalue. (D) Predicted 
class plot vs. samples used for training and prediction sets (dashed box), where each 
circle marker represents one sample. 
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Tables Legends 
Table 1: Number of training, validation and prediction specimens in each biofluids 
category. 
 
Category – biofluids Training  Validation Prediction 
Normal – plasma 21 7 7 
Normal – serum 22 7 7 
Normal – saliva 22 8 8 
Normal – urine 22 8 8 
Inflammatory – plasma 10 4 4 
Inflammatory – serum 11 4 4 
Inflammatory – saliva 11 4 4 
Inflammatory – urine 11 4 4 
Barrett’s – plasma 17 5 5 
Barrett’s – serum 18 5 5 
Barrett’s – saliva 17 5 5 
Barrett’s – urine 17 5 5 
LGD – plasma 3 1 2 
LGD – serum 3 1 2 
LGD – saliva 3 1 2 
LGD – urine 3 1 2 
HGD – plasma 7 2 3 
HGD – serum 7 2 3 
HGD – saliva 7 2 3 
HGD – urine 6 2 3 
OAC – plasma 12 5 5 
OAC – serum 14 4 4 
OAC – saliva 15 5 5 
OAC – urine 15 5 5 
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